p24CE + p55gag + IL-12 + MVA62B + bNAbs

This experimental combinatorial HIV therapeutic regimen is being developed through a collaboration between the **University of California, San Francisco (UCSF)** and **Ichor Medical Systems**. The regimen utilizes a multi-modal "prime-boost" strategy combined with passive immunotherapy to achieve HIV remission or a functional cure. It consists of DNA vaccines encoding the HIV conserved element **p24 (p24CE)** and **p55gag** antigens, delivered via electroporation (likely using Ichor's TriGrid system). An **interleukin-12 (IL-12)** plasmid DNA serves as a molecular adjuvant to enhance cellular immune responses. This is followed by a boost with the **MVA62B** viral vector (Modified Vaccinia Ankara). Additionally, the regimen incorporates **broadly neutralizing antibodies (bNAbs)** to provide passive immunity, neutralize circulating virus, and potentially clear infected cells. The p24CE component is specifically designed to focus the immune response on highly conserved viral regions to prevent immune escape.

Other names

p24CE + interleukin-12 + p55gag + MVA62B + broadly neutralizing antibodiesUCSF HIV therapeutic vaccine regimen